You can buy or sell ATOS and other stocks, options, ETFs, and crypto commission-free!
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. Read More The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
52 Week High
52 Week Low
Seeking AlphaMar 18
Atossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One Patient
Atossa Genetics Inc. (ATOS) had a wild week last week after announcing that its proprietary oral Endoxifen was granted "Expanded Access" by the FDA for Post-Mastectomy Treatment for a U.S. Breast Cancer Patient. Third time was apparently a charm since the company announced it was originally given Expanded Access prior to the operation on December 3 and positive results were reported on February 7. Both updates resulted in a lot of volume being traded on the stock on those particular days but minimal price m...
Yahoo FinanceMar 18
Atossa Genetics Announces Receipt of $10 Million
Cash Proceeds from Exercise of Outstanding Warrants SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that on March 14 and 15, 2019, it received approximately $10 million from exercises of previously outstanding warrants. The warrants were issued by the Company in the rights offering completed May 30, 2018. As result of the ...
-$0.63 per share
Expected Mar 22, After Hours